Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial.

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) necessitates long-term management to avert disease progression.
• Immunoglobulin therapy is a common treatment for CIDP, but its discontinuation can lead to worsening symptoms.

Purpose of the Study:

• To assess the efficacy of rituximab in preventing clinical worsening in CIDP patients after discontinuing immunoglobulin therapy.
• To compare the rates of deterioration between rituximab and placebo groups following immunoglobulin withdrawal.

Main Methods:

• A randomized, double-blind, placebo-controlled study involving 37 CIDP patients across seven Italian hospitals.
• Patients received either rituximab (1g on Days 1, 15, 180 ± 7) or placebo, alongside continued regular immunoglobulin doses for 6 months post-intervention.
• Primary endpoint: proportion of patients worsening at Month 12 (defined by INCAT, MRC, or RODS scores) within 6 months after immunoglobulin discontinuation.

Main Results:

• No significant difference in worsening rates at Month 12 (63.2% rituximab vs. 66.6% placebo) or Month 18 was observed.
• Mean scores on adjusted INCAT, MRC sum, and RODS centile scales showed no significant differences between groups at Months 6, 12, and 18.
• Median time to worsening was comparable: 5 months for rituximab versus 2 months for placebo (Log-rank P = 0.4372).

Conclusions:

• Rituximab demonstrated no superior efficacy over placebo in preventing clinical deterioration in CIDP patients after immunoglobulin therapy cessation.
• Further research may explore alternative rituximab administration schedules, such as earlier or more frequent dosing, for potential benefit in CIDP management.